Literature DB >> 16050141

The homogeneous multiplexed system--a new method for autoantibody profile in systemic lupus erythematosus.

Gisele Zandman-Goddard1, Boris Gilburd, Ora Shovman, Miri Blank, Svetlana Berdichevski, Pnina Langevitz, Yehuda Shoenfeld.   

Abstract

Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease leading to immunological aberrations and excessive multiple autoantibody production. The aim of this study was to investigate the prevalence of multiple autoantibodies in SLE patients utilizing the multiplex system method. We analyzed the presence of elevated titers of anti-Ro, anti-La, anti-RNP, anti-Sm, anti-Jo1, anti-centromere, anti-Scl-70, anti-histone, and anti-dsDNA antibodies in 199 serum samples (113 SLE patients, 86 healthy donors). We compared the type, level and number of autoantibodies and the correlation between the autoantibody profile and disease severity utilizing the SLEDAI score. Elevated titers of at least one autoantibody were detected in 48% of 42 SLE patients. Elevated titers of anti-Ro antibodies were most commonly detected. The distribution of specific autoantibodies was: anti-Ro- 23.8%, anti-dsDNA- 19%, antihistone- 19%, anti-RNP- 14.2%, anti-La antibodies- 11.9%, anti-Sm- 7.1%, anti-Scl 70-4.7%, and anti-centromere- 2.4%. Utilizing ROC analysis, the sensitivity and specificity of anti-DNA antibodies at a cutoff value of 34 IU/ml were 87.1% and 79.4% respectively. Elevated titers of anti-Jo1 antibody were not detected. There was a correlation with the titer of anti-Ro antibodies and disease activity by the SLEDAI score. Seven patients harbored one autoantibody only, 15 patients harbored 2-3 autoantibodies, 3 patients harbored 4-5 autoantibodies, and one patient harbored 6 autoantibodies. A correlation between the number of autoantibodies per patient and disease severity was found. One patient with a multitude of autoantibodies had severe lupus and a myriad of clinical manifestations. In conclusion, the multiplex system is specific and sensitive, provides an autoantibody profile in a single test, and may be useful as a diagnostic test for SLE. Elevated anti-Ro antibodies are associated with severe disease. An autoantibody load may be indicative of more severe disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16050141      PMCID: PMC2270732          DOI: 10.1080/17402520500116723

Source DB:  PubMed          Journal:  Clin Dev Immunol        ISSN: 1740-2522


  6 in total

1.  Prevalence and clinical significance of 15 autoantibodies in patients with new-onset systemic lupus erythematosus.

Authors:  W-X Li; H-F Pan; L-H Li; N Zhang; J Li; Y-G Fan; J-B Feng; X-W Tang; H Chen; X-P Li; D-Q Ye
Journal:  Ir J Med Sci       Date:  2010-08-08       Impact factor: 1.568

2.  Adaptor protein SLAT modulates Fcgamma receptor-mediated phagocytosis in murine macrophages.

Authors:  Harshini Mehta; Michael Glogauer; Stephane Bécart; Amnon Altman; K Mark Coggeshall
Journal:  J Biol Chem       Date:  2009-02-27       Impact factor: 5.157

3.  Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting.

Authors:  Kate LaRiviere Homer; Jeffrey Warren; Dmitry Karayev; Puja P Khanna; Amber Young; Vivek Nagaraja; Allan L Metzger; Dinesh Khanna
Journal:  J Clin Rheumatol       Date:  2020-04       Impact factor: 3.902

4.  Automated Processing and Evaluation of Anti-Nuclear Antibody Indirect Immunofluorescence Testing.

Authors:  Vincent Ricchiuti; Joseph Adams; Donna J Hardy; Alexander Katayev; James K Fleming
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

5.  Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile.

Authors:  Diana Carmona-Fernandes; Maria José Santos; Helena Canhão; João Eurico Fonseca
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

Review 6.  Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.

Authors:  Mandy Sowa; Rico Hiemann; Peter Schierack; Dirk Reinhold; Karsten Conrad; Dirk Roggenbuck
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.